FMP
Sep 10, 2021(Last modified: Dec 19, 2023)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares were trading around 50% lower today following the company’s mixed top-line results from its Phase 3 DERBY and OAKS studies of pegcetacoplan in geographic atrophy (GA).
Analysts at Oppenheimer lowered their price target on the company’s shares to $65 from $80, adjusting its model, which incorporates an updated PoS of 75% in the US for GA (from 60% previously), but moderate their estimates for potential sales and timing of approval (1H22 FDA filing, ~one year delay in EU). The brokerage awaits additional assessment of these data (Retina Society meeting 09/29-10/02) and feedback from the agency.

In times of rising geopolitical tension or outright conflict, defense stocks often outperform the broader market as gove...

As Circle Internet (NYSE:CRCL) gains attention following its recent public listing, investors are increasingly scrutiniz...

LVMH Moët Hennessy Louis Vuitton (OTC:LVMUY) is a global leader in luxury goods, offering high-quality products across f...